NCT06681181View on ClinicalTrials.gov

A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

October 23, 2025

Study Completion Date

September 9, 2026

Conditions

Colitis, Ulcerative

Interventions

DRUG

GSK4528287

GSK4528287 will be administered.

DRUG

Placebo

Placebo will be administered.

Trial Locations (1)

CB2 0GG

RECRUITING

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT06681181 - A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants | Biotech Hunter | Biotech Hunter